Anavex Life Sciences Corp (AVXL)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $75.79M
Last updated: Nov 17, 2026 at 4:40 PM ET
Anavex Life Sciences Corp (AVXL) Statistics
Anavex Life Sciences (AVXL) has a market cap of $75.79M. It holds $118.33M more cash than debt, 156.13% of its market cap. Its share count is up 8.57% from a year earlier.
Total Valuation
| Market Cap | $75.79M |
|---|---|
| Latest price (Nov 17, 2026) | $0.74 |
Key Dates
The next earnings report is expected on Nov 23, 2026, covering the quarter ending Sep 30, 2026.
| Next Earnings Date | Nov 23, 2026 (expected) |
|---|---|
| Last Earnings Date | Jul 30, 2026 |
| Fiscal Year End | September |
Price Statistics
The stock is down 79.70% over 52 weeks and trades 55.69% below its 50-day average.
| Beta (1Y) | 2.13 |
|---|---|
| 52-Week Change | -79.70% |
| 1-Month Change | -40.80% |
| 3-Month Change | -78.17% |
| 6-Month Change | -72.28% |
| 5-Year Change | -93.65% |
| 10-Year Change | -57.35% |
| Total Return (1Y) | -79.70% |
| Total Return (3Y CAGR) | -50.94% |
| Total Return (5Y CAGR) | -48.37% |
| Max Drawdown (1Y) | -86.04% |
| Max Drawdown (3Y) | -94.50% |
| Sharpe Ratio (1Y) | -1.81 |
| Correlation with SPY (1Y) | 0.34 |
| 50-Day Average | $1.67 |
| 200-Day Average | $2.86 |
| 52-Week Range | $0.80 to $5.36 |
| RSI (14 Days) | 20.3 |
| Average Volume (20 Days) | 1.18M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 15.62x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 15.62x |
|---|---|
| Quick Ratio | 15.62x |
| Debt / Equity | 0.00x |
| Interest Coverage | 4.14x |
Returns and Efficiency
Return on equity is -11.58% over the last 12 months, against a 5-year average of -35.39%.
| Return on Equity (ROE) | -11.58% |
|---|---|
| Return on Assets (ROA) | -10.84% |
| ROE (5Y Average) | -35.39% |
| ROA (5Y Average) | -32.41% |
| ROIC (5Y Average) | -36.41% |
Scores
AVXL has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 2 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Operating Income | -$17.37M |
| Pretax Income | -$13.00M |
| Net Income | -$13.02M |
| Reported EPS (TTM) | -$0.22 |
Trailing 12 months through Jun 30, 2026.
Balance Sheet
Shareholder equity funds 93.60% of the $120.14M in total assets.
| Cash and Equivalents | $118.33M |
|---|---|
| Total Debt | $0 |
| Net Cash | $118.33M |
| Net Cash Per Share | $1.28 |
| Working Capital | $112.45M |
| Shareholder Equity | $112.45M |
| Book Value Per Share | $1.21 |
| Total Assets | $120.14M |
| Total Liabilities | $7.69M |
Balance sheet as of Jun 30, 2026.
Cash Flow
| Operating Cash Flow | -$32.66M |
|---|---|
| FCF Per Share | -$0.35 |
Trailing 12 months through Mar 31, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | -21.18% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | -21.18% |
Dividends and Yields
AVXL does not pay a dividend.
| Buyback Yield | -66.52% |
|---|---|
| Shareholder Yield | -66.52% |
Stock Splits
The last split was a 1-for-4 reverse split on Oct 7, 2015.
| Last Split Date | Oct 7, 2015 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:4 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About AVXL
What is AVXL's market cap?
Anavex Life Sciences has a market cap of $75.79M.
How many shares of AVXL are outstanding?
Anavex Life Sciences has 92.70M shares outstanding. The count is up 8.57% from a year earlier.
Does AVXL pay a dividend?
No. Anavex Life Sciences does not pay a dividend.
How much debt does AVXL have?
Anavex Life Sciences has $0 of total debt and $118.33M of cash and equivalents, a net cash position of $118.33M.
AVXL pages: Overview, Charting, Earnings, Forecast, Financials, Statistics